拉米夫定对慢性乙型肝炎的抗病毒疗效与Th1/Th2变化的关系

阎双缓; 张新元; 曹治宸; 陈翠英; 王素平; 唐亚芳

拉米夫定对慢性乙型肝炎的抗病毒疗效与Th1/Th2变化的关系

1. 石家庄市第五医院感染五科
2. 河北医科大学第三医院肝病科

基金项目:

河北省科技厅资助项目(编号07276101D-34)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1908
- HTML全文浏览量: 25
- PDF下载量: 764
- 被引次数: 0
出版历程
- 出版日期: 2009-03-20

Relationship between the Antiviral Effect and Changes of Th1/Th2 during the Treatment of Chronic Hepatitis B Using Lamivudine.

Research funding:

摘要

摘要: 目的观察拉米夫定（LAM）治疗前后患者血清Th1/Th2比值的动态变化。方法用酶联免疫吸附（ELISA）方法分别检测60例慢性乙型肝炎患者在拉米夫定治疗前,治疗后第3、6、9、12月时的血清IFN-γ和IL-4水平。选取20名健康献血员作为正常对照。结果LAM治疗前ALT高水平组IFN-γ水平及IFN-γ/IL-4比值较高,完全应答率较高,无应答率较低;治疗后完全应答组IFN-γ/IL-4水平接近或高于对照组,部分应答组和无应答组IFN-γ/IL-4水平低于对照组。结论拉米夫定治疗慢性乙型肝炎可增加Th1类细胞因子IFN-γ分泌,抑制Th2类细胞因子IL-4分泌,治疗后Th1/Th2平衡的恢复与抗病毒疗效有关。T细胞免疫功能的恢复是抗病毒治疗的关键之一。
- 慢性乙型肝炎 /
- 拉米夫定 /
- Th1/Th2 /
- ALT
Abstract: Objective To investigate changes in serum Th1/Th2 ratios of patients with chronic hepatitis B during Lamivudine treatment.Methods Serum INF-γ and IL-4 levels were determined by ELISA in 60 patients with chronic hepatitis B at baseline and 3, 6, 9 and 12 months during treatment.At the same time, and 20 healthy volunteers were served as normal control.Results The patients with high ALT levels showed higher IFN-γ levels and IFN-γ/IL-4 ratios than those with low ALT levels, and they showed higher rate of complete response and lower rate of non-response to LAM treatment.After treatment, the ratios of IFN-γ to IL-4 in complete response patients were approximate to those of control group, sometimes even higher than them.The ratios of IFN-γ to IL-4 in partial response and non response patients were lower than those of control group.Conclusion LAM can increase the release of IFN-γ (cytokines of Th1 type) , whereas inhibit IL-4 (cytokines of Th2 type) levels.The antiviral effect is related to the recovery of Th1/Th2 balance.The reconstruction of the T lymphocyte function in vivo is an important aspect in antiviral treatment.
- chronic hepatitis B /
- Lamivudine /
- Th1/Th2 /
- ALT

HTML全文

参考文献(10)

[1]中华医学会.病毒性肝炎防治方案[J].中华传染病学杂志, 2001, 19 (1) ∶56-62.

[2]拉米夫定临床应用专家组.2004年拉米夫定临床应用专家共识[J].中华传染病学杂志, 2004, 12 (7) ∶425-428.

[3]Lee M, Lee SK, Son M, et al.Expression of Th1 and Th2 type cyto-kines responding to HBsAg in chronic hepatitisB patients[J].KoreanMed Sci, 1999, 14 (2) ∶175-181.

[4]Penna A, Del PG, Cavalli A, et al.Predominant Thelper1 cytokineprofile of hepatitis B virus nucleocapsid pecific Tcells in acute self-limited hepatitis B[J].Hepatology, 1997, 25 (4) ∶1022-1027.

[5]姜荣龙, 卢桥生, 骆抗先, 等.慢性乙型肝炎病毒感染者外周血T辅助细胞1、2型因子的表达[J].中华传染病杂志, 2000, 18 (1) ∶26-28.

[6]俞富军, 何生松, 张淑玲。拉米夫定对慢性乙肝患者IL-2和IL-4影响的初步探讨[J].安徽医学, 2006, 27 (1) :27-29.

[7]何登明, 毛青.拉米夫定治疗对慢性乙型肝炎患者Th1/Th2平衡的影响及意义[J].中华肝脏病杂志, 2004, 12 (8) :495-496.

[8]彭文伟.传染病学[M].北京:人民卫生出版社, 2000∶43.

[9]Pol S, Michel ML, Brechot C, et al.Immune therapy of hepatitis Bvirus chronic infection[J].Hepatology, 2000, 31 (2) ∶548-549.

[10]陈紫荣.病毒性肝炎[M].北京:人民卫生出版社, 2001∶423.

施引文献

资源附件(0)

访问统计